Vaxxas Announces Interim Results from Phase I Clinical Study

CAMBRIDGE, Mass. & BRISBANE, Australia--(BUSINESS WIRE)--Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced positive interim results from a

Related Keywords

Australia , Brisbane , Queensland , Cambridge , Cambridgeshire , United Kingdom , United States , Australian , Kathryn Morris , Davidl Hoey , Amy Miller , University Of Queensland , Development Authority , International Convention , Yates Network , Australian Government Innovation Investment Fund , United States Biomedical Advanced Research , Oneventures Innovation Fund , Vaxxas Chief Executive Officer David , Science Advances , Brandon Capital Partners , Brandon Biocatalyst , Healthcare Ventures , Australian Government , Innovation Investment Fund , Press Release , ,